Trends in Bioinformatics and Chemoinformatics of vitamin D analogs and their protein targets

Current Bioinformatics

Volumn 6, Issue 1, 2011, Pages 16-24

  García, Isela ^a   Fall, Yagamare ^a   Gómez, Generosa ^a  

^a UNIVERSITY OF VIGO   (Spain)

Author keywords

Calcitriol; COMFA; Docking; QSAR; Vitamin D3

Indexed keywords

BIOLOGICAL SYSTEMS; COMPUTATIONAL CHEMISTRY; DISTRIBUTION FUNCTIONS; VITAMINS;

BIOLOGICAL FUNCTIONS; CALCITRIOL; CHEMOINFORMATICS; COMFA; DOCKING; QSAR; QSAR STUDIES; STRUCTURAL REQUIREMENTS; VITAMIN D3; VITAMIN-D;

REGRESSION ANALYSIS;

COLECALCIFEROL; ECDYSTEROID; ENZYME INHIBITOR; HYDRAZINE DERIVATIVE; RETINOIC ACID RECEPTOR; RH 5849; TEBUFENOZIDE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ARTICLE; BIOINFORMATICS; DRUG ACTIVITY; DRUG STABILITY; DRUG STRUCTURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; PROTEIN TARGETING; SEQUENCE ALIGNMENT; X RAY DIFFRACTION;

EID: 79953871169     PISSN: 15748936     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489311795222383     Document Type: Article

References (73)

1. Cernakova M, Kost'alova D, Kettmann V, Plodova M, Toth J, Drimal J. Potential antimutagenic activity of berberine, a constituent of Mahonia aquifolium. BMC Comp Altern Med 2002; 2: 2.
2. Cao JW, Luo HS, Yu BP, Huang XD, Sheng ZX, Yu JP. Effects of berberine on intracellular free calcium in smooth muscle cells of Guinea pig colon. Digestion 2001; 64: 179-83.
3. Jang MJ, Jwa M, Kim JH, Song K. Selective inhibition of MAPKK Wis1 in the stress-activated MAPK cascade of Schizosaccharomyces pombe by novel berberine derivatives. J Biol Chem 2002; 277: 12388-95.
4. Li BX, Yang BF, Zhou J, Xu CQ, Li YR. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes. Acta Pharmacol Sin 2001; 22: 125-31.
5. Choi DS, Kim SJ, Jung MY. Inhibitory activity of berberine on DNA strand cleavage induced by hydrogen peroxide and cytochrome c. Biosci Biotechnol Biochem 2001; 65: 452-5.
6. Iizuka N, Miyamoto K, Okita K, et al. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett 2000; 148: 19-25.
7. Li H, Miyahara T, Tezuka Y, et al. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull 1999; 22: 391-6.
8. Chou KC. Structural bioinformatics and its impact to biomedical science. Curr Med Chem 2004; 11: 2105-34.
9. Chou KC, Wei DQ, Du QS, Sirois S, Zhong WZ. Progress in computational approach to drug development against SARS. Curr Med Chem 2006; 13: 3263-70.
10. Todeschini R, Consonni V. Handbook of Molecular Descriptors. Wiley-VCH 2002.
11. Estrada E., Uriarte E. Recent advances on the role of topological indices in drug discovery research. Curr Med Chem 2001; 8: 1573-88.
12. González-Díaz H, González-Díaz Y, Santana L, Ubeira FM, Uriarte E. Proteomics, networks and connectivity indices. Proteomics 2008; 8: 750-78.
13. Torrens F, Castellano G. Topological charge-transfer indices: from small molecules to proteins. Curr Proteomics 2009: 204-13.
14. Concu R, Dea-Ayuela MA, Perez-Montoto LG, et al. 3D entropy and moments prediction of enzyme classes and experimentaltheoretic study of peptide fingerprints in Leishmania parasites. Biochim Biophys Acta 2009; 1794: 1784-94.
15. Ivanciuc O. Machine learning Quantitative Structure-Activity Relationships (QSAR) for peptides binding to Human Amphiphysin-1 SH3 domain. Curr Proteomics 2009; 4: 289-302.
16. Vilar S, Gonzalez-Diaz H, Santana L, Uriarte E. A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. J Theor Biol 2009; 261: 449-58.
17. Giuliani A, Di Paola L, Setola R. Proteins as networks: a mesoscopic approach using haemoglobin molecule as case study. Curr Proteomics 2009; 6: 235-45.
18. Chou KC. Pseudo amino acid composition and its applications in bioinformatics, proteomics and system biology. Curr Proteomics 2009; 6: 262-74.
19. Chen J, Shen B. Computational analysis of amino acid mutation: a proteome wide perspective. Curr Proteomics 2009; 6: 228-34.
20. Gonzalez-Diaz H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr Top Med Chem 2008; 8: 1554.
21. Caballero J, Fernandez M. Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr Top Med Chem 2008; 8: 1580-605.
22. Duardo-Sanchez A, Patlewicz G, Lopez-Diaz A. Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr Top Med Chem 2008; 8: 1666-75.
23. Gonzalez MP, Teran C, Saiz-Urra L, Teijeira M. Variable selection methods in QSAR: an overview. Curr Top Med Chem 2008; 8: 1606-27.
24. Gonzalez-Diaz, H, Prado-Prado F, Ubeira FM. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr Top Med Chem 2008; 8: 1676-90.
25. Helguera AM, Combes RD, Gonzalez MP, Cordeiro MN. Applications of 2D descriptors in drug design: a DRAGON tale. Curr Top Med Chem 2008; 8: 1628-55.
26. Ivanciuc O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr Top Med Chem 2008; 8: 1691-709.
27. Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 2008; 8: 1555-72.
28. Wang JF, Wei DQ, Chou KC. Drug candidates from traditional chinese medicines. Curr Top Med Chem 2008; 8: 1656-65.
29. Wang JF, Wei DQ, Chou KC. Pharmacogenomics and personalized use of drugs. Curr Top Med Chem 2008; 8: 1573-9.
30. Lin YY, Qi Y, Lu JY, et al. A comprehensive synthetic genetic interaction network governing yeast histone acetylation and deacetylation. Genes Dev 2008; 22: 2062-74.
31. Zhong WZ, Zhan J, Kang P, Yamazaki S. Gender specific drug metabolism of PF-02341066 in rats-role of sulfoconjugation. Curr Drug Metab 2010; 11: 296-306.
32. Wang JF, Chou KC. Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab 2010; 11: 342-6.
33. Mrabet Y, Semmar N. Mathematical methods to analysis of topology, functional variability and evolution of metabolic systems based on different decomposition concepts. Curr Drug Metab 2010; 11: 315-41.
34. Martinez-Romero M, Vazquez-Naya JM, Rabunal JR, et al. Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. Curr Drug Metab 2010; 11: 347-68.
35. Khan MT. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr Drug Metab 2010; 11: 285-95.
36. Gonzalez-Diaz H, Duardo-Sanchez A, Ubeira FM, et al. Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr Drug Metab 2010; 11: 379-406.
37. Gonzalez-Diaz H. Network topological indices, drug metabolism, and distribution. Curr Drug Metab 2010; 11: 283-4.
38. Garcia I, Diop YF, Gomez G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr Drug Metab 2010; 11: 307-14.
39. Chou KC. Graphic rule for drug metabolism systems. Curr Drug Metab 2010; 11: 369-78.
40. Concu R, Podda G, Ubeira FM, Gonzalez-Diaz H. Review of QSAR models for enzyme classes of drug targets: Theoretical background and applications in parasites, hosts, and other organisms. Curr Pharm Design 2010; 16: 2710-23.
41. Estrada E, Molina E, Nodarse D, Uriarte E. Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach. Curr Pharm Design 2010; 16: 2676-709.
42. Garcia I, Fall Y, Gomez G. QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr Pharm Design 2010; 16: 2666-75.
43. Gonzalez-Diaz H. QSAR and complex networks in pharmaceutical design, microbiology, parasitology, toxicology, cancer, and neurosciences. Curr Pharm Design 2010; 16: 2598-600.
44. Gonzalez-Diaz H, Romaris F, Duardo-Sanchez A, et al. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues. Curr Pharm Design 2010; 16: 2737-64.
45. Marrero-Ponce Y, Casanola-Martin GM, Khan MT, Torrens F, Rescigno A, Abad C. Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr Pharm Design 2010; 16: 2601-24.
46. Munteanu CR, Fernandez-Blanco E, Seoane JA, et al. Drug discovery and design for complex diseases through QSAR computational methods. Curr Pharm Design 2010; 16: 2640-55.
47. Roy K, Ghosh G. Exploring QSARs with Extended Topochemical Atom (ETA) indices for modeling chemical and drug toxicity. Curr Pharm Design 2010; 16: 2625-39.
48. Speck-Planche A, Scotti MT, de Paulo-Emerenciano V. Current pharmaceutical design of antituberculosis drugs: future perspectives. Curr Pharm Design 2010; 16: 2656-65.
49. Vazquez-Naya JM, Martinez-Romero M, Porto-Pazos AB, et al. Ontologies of drug discovery and design for neurology, cardiology and oncology. Curr Pharm Design 2010; 16: 2724-36.
50. Tan YL, Goh D, Ong ES. Investigation of differentially expressed proteins due to the inhibitory effects of berberine in human liver cancer cell line HepG2. Mol Biosyst 2006; 2: 250-8.
51. Xu L, Liu Y, He X. Inhibitory effects of berberine on the activation and cell cycle progression of human peripheral lymphocytes. Cell Mol Immunol 2005; 2: 295-300.
52. Gonzalez MP, Gandara Z, Fall Y, Gomez G. Radial distribution function descriptors for predicting affinity for vitamin D receptor. Eur J Med Chem 2008; 43(7): 1360-5.
53. Gonzalez MP, Puente M, Fall Y, Gomez G. In silico studies using Radial Distribution Function approach for predicting affinity of 1 alpha,25-dihydroxyvitamin D(3) analogues for Vitamin D receptor. Steroids 2006; 71: 510-27.
54. Jensen BF, Sorensen MD, Kissmeyer AM, et al. Prediction of in vitro metabolic stability of calcitriol analogs by QSAR. J Comput Aided Mol Des 2003; 17: 849-59.
55. Wang F, Zhou HY, Zhao G, et al. Inhibitory effects of berberine on ion channels of rat hepatocytes. World J Gastroenterol 2004; 10: 2842-5.
56. Ravi M, Hopfinger AJ, Hormann RE, Dinan L. 4D-QSAR analysis of a set of ecdysteroids and a comparison to CoMFA modeling. J Chem Inf Comput Sci 2001; 41: 1587-604.
57. Cernakova M, Kostalova D. Antimicrobial activity of berberine--a constituent of Mahonia aquifolium. Folia Microbiologica 2002; 47: 375-8.
58. Fink H. [On the problem of the minimal inhibitory concentration (MIC) of oxacillin against staphylococci]. Arzneimittel-Forschung 1965; 15: 630-2.
59. Tamura M, Takano S. [Influence of pH of media on the minimal inhibitory concentration of cycloserine to Mycobacterium tuberculosis]. Kekkaku 1965; 40: 213-8.
60. Miura T. Morphological observations of the influence of some chemical drugs on the growth of dermatophytes at concentrations directly below the minimal inhibitory concentration. Tohoku J Exp Med 1963; 80: 103-17.
61. Linser H. [The mechanism of action of growth and inhibitory substances. IV. The concentration-activity curves of various synthetic cell-elongating growth substances in the presence of various quantities of synthetic inhibitors.]. Biochim et Biophys Acta 1954; 15: 25-30.
62. Gero E. [Inhibitory action of vitamin B1 on the oxidation of Lascorbic acid. II. Influence of pH and of the vitamin B1 concentration; role of the various moieties of the vitamin B1 molecule.]. Bull de la Soc de Chimie Biol 1954; 36: 1335-42.
63. Raska SB. The metabolism of the kidney in experimental renal hypertension: ii. The concentration of cytochrome C and the activities of the Cytochrome oxidase and of the succinic dehydrogenase systems in the kidney of dogs with experimental renal hypertension. The inhibitory effect of renin and of kidney tissue preparations from hypertensive dogs on the respiratory enzymes. J Exp Med 1945; 82: 227-40.
64. Shaffer PL, Gewirth DT. Structural analysis of RXR-VDR interactions on DR3 DNA. J Steroid Biochem Mol Biol 2004; 89-90: 215-9.
65. Germain P, Kammerer S, Peluso-Iltis C, et al. Rational design of RAR-selective ligands revealed by RARbeta crystal structure. Embo Rep 2004; 5: 877-82.
66. Klaholz BP, Mitschler A, Belema M, Zusi C, Moras D. Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma. Proc Natl Acad Sci USA 2000; 97: 6322-7.
67. Renaud J.-P, Rochel N, Ruff M, Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995; 378: 681-9.
68. Renaud J.-P, Rochel N, Ruff M, Moras D. The solution structure of the human retinoic acid receptor-beta DNA-binding domain. J Biomol NMR 1995; 3: 1-17.
69. Kong W, Li Z, Xiao X, Zhao Y. Microcalorimetric investigation of the toxic action of berberine on Tetrahymena thermophila BF(5). J Basic Microbiol 2010; 50(5): 436-41.
70. Zhang S, Zhang B, Xing K, Zhang X, Tian X, Dai W. Inhibitory effects of golden thread (Coptis chinensis) and berberine on Microcystis aeruginosa. Water Sci Technol 2010; 61: 763-9.
71. Liu L, Yu YL, Yang JS, et al. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn-Schmiedebergs Arch Pharm 2010; 381: 371-81.
72. Yu Y, Liu L, Wang X, Liu X, Xie L, Wang G. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol 2010; 79: 1000-6.
73. Yang HZ, Zhou MM, Zhao AH, Xing SN, Fan ZQ, Jia W. [Study on effects of baicalin, berberine and Astragalus polysaccharides and their combinative effects on aldose reductase in vitro]. Zhong Yao Cai 2009; 32: 1259-61.